Overall, GLP-1-based therapies represent a promising platform for addressing interconnected metabolic and non-metabolic diseases, however, the strength of evidence varies substantially across indications, highlighting the need for well-designed clinical trials, long-term safety evaluation, and clearer identification of...
Preeti Sah, Z. Husain, Kashish Verma Verma et al.· Journal of Pharmacology, Gen...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.